Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rectal indomethacin and/or papillary adrenaline spray for prevention of post-ERCP pancreatitis
PACTR202501795806576Phase 3Recruiting
- Sponsor
- Al-Azhar University
- Start
- Jan 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of indomethacin and epinephrine in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (4 arms), sponsored by Al-Azhar University. Started Jan 2025; status: recruiting.
02
Drugs
indomethacinepinephrine
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on PACTR202501795806576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202501795806576.